4//SEC Filing
Segal Lloyd Mitchell 4
Accession 0001209191-21-038747
CIK 0001808158other
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 6:36 PM ET
Size
15.2 KB
Accession
0001209191-21-038747
Insider Transaction Report
Form 4
Segal Lloyd Mitchell
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2021-06-04−5,000→ 283,683 totalExercise: $1.64Exp: 2027-06-22→ Common Stock (5,000 underlying) - Sale
Common Stock
2021-06-03$31.74/sh−6,648$211,008→ 126,936 total(indirect: See footnote) - Sale
Common Stock
2021-06-04$31.36/sh−12,172$381,714→ 97,584 total(indirect: See footnote) - Sale
Common Stock
2021-06-04$31.25/sh−5,000$156,250→ 5,000 total - Sale
Common Stock
2021-06-04$30.64/sh−17,180$526,395→ 109,756 total(indirect: See footnote) - Exercise/Conversion
Common Stock
2021-06-04$1.64/sh+5,000$8,185→ 10,000 total
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5).
- [F2]These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.19 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.215 to $31.65 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.49 inclusive.
- [F6]Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Documents
Issuer
Repare Therapeutics Inc.
CIK 0001808158
Entity typeother
Related Parties
1- filerCIK 0001477123
Filing Metadata
- Form type
- 4
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 6:36 PM ET
- Size
- 15.2 KB